SCHEMBL7678280

SCHEMBL7678280

CCC(Oc1ccc(-c2cn3ccccc3n2)cc1)N(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 13/20 0.64
NPC1 O15118 12/20 0.64
ALDH1A1 P00352 8/20 0.64
SMN1; SMN2 Q16637 7/20 0.64
PKM P14618 4/20 0.64
MAPK1 P28482 2/20 0.64
KDM4E B2RXH2 8/20 0.61
NFKB1 P19838 1/20 0.61
NFKB2 Q00653 1/20 0.61
RELA Q04206 1/20 0.61
EPHX2 P34913 1/20 0.61
HRH3 Q9Y5N1 2/20 0.57
GFER P55789 3/20 0.52
HPGD P15428 3/20 0.52
POLB P06746 1/20 0.51
HDAC6 Q9UBN7 1/20 0.49
PTGS1 P23219 1/20 0.48
PTGS2 P35354 1/20 0.48
ADRB2 P07550 1/20 0.47
HSD17B10 Q99714 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7681802 0.85 HRH3 (0.67) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL5416400 0.83 RAB9A (0.67) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL7681716 0.81 HRH3 (0.61) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13325732 0.78 RAB9A (1.00) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL5429085 0.78 RAB9A (0.60) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL9293443 0.76 NPC1 (1.00) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL19322156 0.76 NPC1 (0.90) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13325926 0.76 RAB9A (0.77) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL13325909 0.76 RAB9A (0.83) RAB9ANPC1ALDH1A1SMN1; SMN2PKM
SCHEMBL7678283 0.75 HRH3 (0.79) RAB9ANPC1ALDH1A1SMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6489337-B1 TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-12-03 US claimed
WO-2001074813-A2 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO claimed
US-6489337-B1 TREATMENT OF ALZHEIMER'S DISEASE, EPILEPSY, EATING DISORDERS, LEARNING AND MEMORY DISORDERS, MIGRAINE, SLEEP/WAKE DISORDERS, ALLERGIC RHINITIS, SCHIZOPHRENIA, MILD COGNITIVE IMPAIRMENT, AND ASTHMA ORTHO-MCNEIL PHARMACEUTICAL, INC. 2002-12-03 US disclosed
WO-2001074813-A2 METHOD FOR USING 2- OR 3-ARYL SUBSTITUTED IMIDAZO[1,2-a] PYRIDINES AS H3 ANTAGONISTS ORTHO MCNEIL PHARMACEUTICAL, INC. (US) 2001-10-11 WO disclosed